MX2009006755A - Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada. - Google Patents

Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada.

Info

Publication number
MX2009006755A
MX2009006755A MX2009006755A MX2009006755A MX2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A MX 2009006755 A MX2009006755 A MX 2009006755A
Authority
MX
Mexico
Prior art keywords
cells
rna viruses
segmented negative
methodology
measles
Prior art date
Application number
MX2009006755A
Other languages
English (en)
Inventor
Pierre Charneau
Frederic Tangy
Yves Jacob
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of MX2009006755A publication Critical patent/MX2009006755A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a células recombinantes así como métodos para la generación de virus de RNA de cadena sencilla de sentido negativo no segmentada (NNV o mononegavirales) de ácido deoxiribonucleico clonado (ADNc), especialmente de virus de sarampión y en forma particular cepas atenuadas tales como las aprobadas para la vacunación, en forma particular de virus de sarampión atenuado Schwarz y varios virus recombinantes con base en sarampión Schwarz que expresan las secuencias heterólogas. Estos virus rescatados pueden utilizarse, después de la amplificación, como vacunas para inmunización en contra de sarampión y/o en contra de péptidos heterólogos o proteínas expresadas.
MX2009006755A 2006-12-22 2007-12-21 Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada. MX2009006755A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06292025.1A EP1939214B1 (en) 2006-12-22 2006-12-22 Cells and methodology to generate non-segmented negative-strand RNA viruses
PCT/IB2007/004444 WO2008078198A2 (en) 2006-12-22 2007-12-21 Cells and methodology to generate non-segmented negative-strand rna viruses

Publications (1)

Publication Number Publication Date
MX2009006755A true MX2009006755A (es) 2009-07-31

Family

ID=37831098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006755A MX2009006755A (es) 2006-12-22 2007-12-21 Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada.

Country Status (11)

Country Link
US (2) US8586364B2 (es)
EP (2) EP1939214B1 (es)
JP (2) JP5902371B2 (es)
KR (1) KR101469007B1 (es)
CN (2) CN104745533A (es)
BR (1) BRPI0719469C1 (es)
CA (1) CA2673262C (es)
DK (2) DK1939214T3 (es)
ES (2) ES2423518T3 (es)
MX (1) MX2009006755A (es)
WO (1) WO2008078198A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233038D1 (de) 2002-06-20 2009-09-03 Pasteur Institut Infektiöse cDNA eines zugelassenen Impfstammes des Masern Virus. Verwendung in immunogenen Zusammensetzungen
ES2427139T3 (es) 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2012038832A2 (en) * 2010-09-24 2012-03-29 Institut Pasteur Generation of replicating chimeric measles virus - retrovirus particles
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
FR2994697B1 (fr) * 2012-08-24 2016-05-13 Centre De Coop Int En Rech Agronomique Pour Le Dev (Cirad) Souche vaccinale marquee du virus de la peste des petits ruminants, et son procede d'obtention
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP2759301A1 (en) 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
GB2550522B (en) 2015-01-05 2020-12-16 Seagull Biosolutions Pvt Ltd DNA molecules producing custom designed replicating and non-replicating negative stranded RNA viruses and uses there of
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
EP3255056A1 (en) * 2016-06-06 2017-12-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses
US11351246B2 (en) 2017-05-09 2022-06-07 Invectys SAS Recombinant measles vaccine expressing hTERT
EP3412307A1 (en) 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
CN107557340A (zh) * 2017-09-26 2018-01-09 南京普菲科医药科技有限公司 一种可诱导性拯救弹状病毒的细胞系及其构建方法与应用
SG11202004234SA (en) 2017-11-09 2020-06-29 Pasteur Institut A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
KR20200104343A (ko) 2017-12-21 2020-09-03 앵스티띠 파스퇴르 라싸 백신
US20210275662A1 (en) * 2018-07-13 2021-09-09 Valneva Se Method for rescuing and producing a virus in avian cells
CN109355301A (zh) * 2018-08-22 2019-02-19 深圳大学 一种石斑鱼重组NNVcp的密码子优化的核酸序列、融合表达载体、制备方法及其本身
CN111218474A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种副粘病毒的拯救系统和副粘病毒拯救方法
EP3673917A1 (en) 2018-12-28 2020-07-01 Themis Bioscience GmbH Norovirus vaccines
CN109913423A (zh) * 2019-03-27 2019-06-21 扬州大学 一种稳定表达猪德尔塔冠状病毒N蛋白的重组Vero细胞系及应用
EP3865180A1 (en) 2020-02-13 2021-08-18 Institut Pasteur Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
CN116472279A (zh) 2020-02-13 2023-07-21 巴斯德研究院 麻疹载体covid-19免疫原性组合物和疫苗
EP4142786A1 (en) * 2020-04-27 2023-03-08 Ohio State Innovation Foundation A live attenuated measles virus vectored vaccine for sars-cov-2
EP3936517A1 (en) * 2020-07-08 2022-01-12 Institut Pasteur An improved measles virus vaccine vector based on multiple tandem additional transcription units
AU2022208199A1 (en) 2021-01-13 2023-07-13 Centre National De La Recherche Scientifique Measles-hiv or measles-htlv vaccine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69510207T3 (de) * 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
ES2377721T3 (es) 1999-10-12 2012-03-30 Institut Pasteur ADN de triple hélice lentiviral, y vectores y células recombinantes que contienen ADN de triple hélice lentiviral
WO2001096376A2 (en) 2000-06-16 2001-12-20 Institut Pasteur Pro-apoptotic fragments of the dengue virus envelope glycoproteins
ES2427139T3 (es) 2002-06-20 2013-10-29 Institut Pasteur Virus recombinantes del sarampión que expresan epítopos de antígenos de virus de ARN y uso de los virus recombinantes para la preparación de composiciones de vacuna
DE10234579A1 (de) * 2002-07-30 2004-02-12 Zf Friedrichshafen Ag Getriebe
CN1871355B (zh) * 2003-06-09 2011-12-14 惠氏 从cDNA中回收非节段性负链RNA病毒的改进方法
DE602004028506D1 (de) 2003-12-02 2010-09-16 Pasteur Institut Neuer mit sars verbunden coronavirus stamm und seine verwendungen
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US20080248067A1 (en) * 2005-04-14 2008-10-09 The University Of Queensland Immunomodulating Compositions and Uses Therefor

Also Published As

Publication number Publication date
EP1939214B1 (en) 2013-07-10
WO2008078198A2 (en) 2008-07-03
ES2423518T3 (es) 2013-09-20
KR101469007B1 (ko) 2014-12-05
ES2686168T3 (es) 2018-10-16
JP2010512779A (ja) 2010-04-30
US9499799B2 (en) 2016-11-22
CN101631798A (zh) 2010-01-20
EP2091962A2 (en) 2009-08-26
BRPI0719469B1 (pt) 2019-07-02
WO2008078198A3 (en) 2008-10-30
DK2091962T3 (en) 2018-10-08
BRPI0719469C1 (pt) 2021-05-25
DK1939214T3 (da) 2013-10-14
JP5902371B2 (ja) 2016-04-13
US20140051148A1 (en) 2014-02-20
EP1939214A1 (en) 2008-07-02
BRPI0719469A2 (pt) 2014-02-11
JP2015015955A (ja) 2015-01-29
KR20090103922A (ko) 2009-10-01
US20100144040A1 (en) 2010-06-10
US8586364B2 (en) 2013-11-19
CA2673262C (en) 2019-03-05
CA2673262A1 (en) 2008-07-03
EP2091962B1 (en) 2018-07-04
CN104745533A (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
MX2009006755A (es) Celulas y metodologia para generar virus de rna de cadena de sentido negativo no segmentada.
Meyer et al. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
WO2012106377A3 (en) Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
IN2012DN00650A (es)
MX2011006205A (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
MX2012000036A (es) Vacuna.
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
WO2009105152A3 (en) Virus-like particles as vaccines for paramyxovirus
MY161965A (en) New influenza virus immunizing epitope
WO2010019262A3 (en) Polyvalent vaccine
MX2012012681A (es) Secuencias del virus de dengue universales y metodos de uso.
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
WO2011034953A3 (en) Lassa virus-like particles and methods of production thereof
WO2011082388A3 (en) Infectious dna vaccines against chikungunya virus
PH12015500308B1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
IN2015DN02546A (es)
MX343830B (es) Molecula de acido nucleico que codifica la proteina nuclear del virus de la hepatitis b y vacuna que comprende la misma.
PH12016502554A1 (en) A dengue virus chimeric polyepitope composed of fragments of non structural proteins and its use in an immunogenic composition against dengue virus infection
WO2012047679A8 (en) Consensus antigen constructs and vaccines made therefrom, and methods of using same to treat malaria
KR20170057384A (ko) 피친데 바이러스 역유전학 시스템 및 이용 방법
WO2011119716A3 (en) Flavivirus host range mutations and uses thereof
AU2013352179A8 (en) Computationally optimized broadly reactive antigens for H1N1 influenza
WO2012038832A3 (en) Generation of replicating chimeric measles virus - retrovirus particles

Legal Events

Date Code Title Description
FG Grant or registration